Model of Translational Medicine for Hepatocelluar Carcinoma

Hao Xing,Han Zhang,Jun Han,Yinan Shen,Feng Shen,Mengchao Wu,Tian Yang

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2016.10.001

2016-01-01

Abstract:Hepatocellular carcinoma (HCC) is a global problem and the second most common cause of cancer related deaths worldwide.Its global incidence is still on the rise.The incidence of HCC in China is high and approximately 55％ of overall cases happened in China.Moreover,there is an undeniable fact that a majority of HCCs are diagnosed at advanced stages when the optimal treatment timing is missed,and advanced HCCs are resistant to most standard chemotherapy regimens.Sorafenib is the only systemic drug approved for the treatment of advanced HCCs.The current researches of HCC included the following components:discovery of biomarkers for early diagnosis,correlation of molecular signatures with radiologic/histologic features,characterization of new druggable targets and personalization of therapy based on individual tumor biology.In this review we focus on advances which have the potential to make transition from bench to bedside and ultimately be beneficial for patients with HCC.